Navigation Links
NeurogesX to Provide Qutenza® Launch Update
Date:2/9/2011

mmercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept, resulting in the commercial launch of Qutenza® (capsaicin) 8% patch in 2010. The Company continues to apply its knowledge and expertise in the development of other novel treatments for pain.

The Company's lead product, Qutenza, is a localized dermal delivery system containing prescription strength capsaicin that is currently approved in the United States and the European Union. Qutenza is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In Europe, Qutenza is being marketed by Astellas Pharma Europe Ltd. (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc., for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain.

The Company is currently preparing to submit a supplemental new drug application (sNDA) to expand the U.S. label for Qutenza for the management of pain due to HIV-associated neuropathy (HIV-AN) also known as HIV-distal sensory neuropathy (HIV-DSP).

The Company's most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed three Phase 1 studies and patient dosing is underway in a Phase 2 clinical trial in PHN patients.

The Company's early-stage pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The Company has evaluated certain of these compounds in vitro and in vivo.

Safe Harbor Statement

<
'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX to Present at Two February Investor Conferences
2. NeurogesX Receives Qutenza®-Specific J-Code From Centers for Medicare and Medicaid Services (CMS)
3. NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
4. NeurogesX to Hold Conference Call to Discuss Third Quarter 2010 Results
5. NeurogesX to Present at Oppenheimer & Co Healthcare Conference
6. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
7. NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
8. NeurogesX Receives FDA Approval of Qutenza(TM) (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
9. NeurogesX Expands Commercial Operations Leadership Team
10. NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
11. NeurogesX to Present at JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , Sept. 1, 2015  Results from an interim ... demonstrate that 5g of idarucizumab enabled emergency surgery ... patients treated with dabigatran (Pradaxa ® dabigatran ... anticoagulant effect of dabigatran enabled patients to be ... time of 1.7 hours between administration of idarucizumab ...
(Date:9/1/2015)... 1, 2015   Ivenix Inc. , a ... system, closed on a $42M round of equity ... Cardinal Partners, CICA, Inc., Easterly Capital, Fidelity Biosciences, ... round. This financing will support the company,s efforts ... Partners LLC acted as the exclusive placement agent ...
(Date:9/1/2015)... 2015 Within just two years after reaching ... rapidly reached 3,000 employees worldwide. This increase is ... injectable drug delivery market and SHL,s effective commitment, ... in the design and manufacturing of auto injectors ... manufacturing capabilities, a lean supply chain, strong partnerships, ...
Breaking Medicine Technology:New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 3New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 4New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 6New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 7New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 8New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 9Ivenix Inc. Secures $42 Million in Funding 2Ivenix Inc. Secures $42 Million in Funding 3SHL Group Reaches Major Milestone of 3000 Employees 2
... 8, 2011 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ... year 2010 financial results before the NASDAQ Global Select Market ... Lief, Arena,s President and Chief Executive Officer, will host a ... Time) to discuss the financial results for the fourth quarter ...
... Sciences: OTC Bulletin Board: RBCL ) -- RBC ... care and pain management products, today reported a 13% increase ... ended December 31, 2010, compared to net sales of $24.9 ... Company reported net earnings of $558,000, or $0.02 per diluted ...
Cached Medicine Technology:Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11 2Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11 3RBC Life Sciences Reports Sales and Earnings Growth in 2010 2RBC Life Sciences Reports Sales and Earnings Growth in 2010 3
(Date:9/1/2015)... ... September 01, 2015 , ... With former IBMers among its founding ... since its inception more than 35 years ago. A pilot program begun by the ... - and, not just those intent on pursuing careers in these fields. The program ...
(Date:9/1/2015)... ... September 01, 2015 , ... Royal River Natural Foods, a locally-owned independent natural ... women for 19 years and found that, among those who had a stroke, people ... report is part of the September 2015 issue of “Natural Insights for Well Being,” ...
(Date:9/1/2015)... Boston, MA (PRWEB) , ... September 01, 2015 , ... ... the little-known and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), will be the beneficiary of ... has the same mission – to raise awareness of the FSH Society and further ...
(Date:9/1/2015)... , ... September 01, 2015 , ... SC&H Group, a ... which includes being named a “Best of the Best” firm in the U.S., as ... named the “Best of the Best” in the U.S., selected exclusively on performance in ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... the 2015-2016 Distinguished Nurse Scholar-in Residence at the Institute of Medicine (IOM) of ... of Biomedical Informatics at Columbia University School of Nursing. A member of the ...
Breaking Medicine News(10 mins):Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2Health News:Columbia Nursing’s Suzanne Bakken Named Distinguished Institute of Medicine Nurse Scholar-in-Residence 2
... diagnosed with primary open angle glaucoma (POAG) are not ... to a study. ,The study is the ... utilize longitudinal data from a nationally representative sample of ... use and surgeries among adults aged 65 and older ...
... says a new study although scientists warn too much reduction ... 1930s it was found that laboratory animals fed a calorie-restricted ... diabetes and cardiovascular disease, but until now, there has been ... lives. ,Now researchers, led by Andrew Dillin at ...
... ready to fight against cancer for the fifth time . ... cancer for the fifth time, started a six-week bout of chemotherapy ... ,He has battled cancer on and off for the last ... course, it's not the greatest news I've ever had but I ...
... babies prone to SIDS and serious health ailments. ... Children in Glasgow have closed in on the possible risk ... risks of cot death. ,Professors Ann Burchell and ... are team leaders of a research group that has zeroed ...
... for promoting good health. The latest news about ... ,Researchers from the University of Wisconsin have ... the infection and avoid what could otherwise lead to ... at the University of Wisconsin introduced this unique therapy ...
... with severe depression who don't respond to other treatments, ... stages of the illness, according to an article ... has been shown to be a highly effective, safe, ... bipolar disorder, and schizophrenia," writes Dr. Stephen Taylor of ...
Cached Medicine News:Health News:Bobby Robson Diagnosed With Cancer for Fifth Time 2Health News:Despite Being Effective Electroconvulsive Therapy is Underused for Severe Depression 2
Delicate Desmarres lid retractors, round serrated handle, very thin blades, polished finish, size 1....
Desmarres Lid Retractor thin solid blades. Size 2....
The Storz Protege is an anterior segment unit only....
... all the features of phaco systems costing ... minimal maintenance. Small, light and tough enough ... Lowest cost reusable tubing kit can be ... there a price objection to purchasing a ...
Medicine Products: